• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.

作者信息

Tosoni Luca, Morelli Gian Luca, Tomadini Gaia, Lazzarotto Davide, Filì Carla, Simeone Erica, Zannier Maria Elena, Callegari Chiara, Fanin Matteo, Battaglia Giulia, Bergnach Melissa, Damiani Daniela, Fanin Renato, Tiribelli Mario

机构信息

Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.

Department of Medicine, University of Udine, Udine, Italy.

出版信息

Blood Cancer J. 2024 Oct 1;14(1):169. doi: 10.1038/s41408-024-01151-2.

DOI:10.1038/s41408-024-01151-2
PMID:39353890
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11448478/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b711/11448478/05532b9bb373/41408_2024_1151_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b711/11448478/05532b9bb373/41408_2024_1151_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b711/11448478/05532b9bb373/41408_2024_1151_Fig1_HTML.jpg

相似文献

1
The triple A (AAA) model globally recapitulates adverse outcomes in essential thrombocythemia.三联A（AAA）模型全面概括了原发性血小板增多症的不良预后。
Blood Cancer J. 2024 Oct 1;14(1):169. doi: 10.1038/s41408-024-01151-2.
2
Occurrence of JAK2V617F mutation in previously triple negative essential thrombocythemia.既往三阴性原发性血小板增多症中JAK2V617F突变的发生情况
Leuk Lymphoma. 2017 Feb;58(2):503-504. doi: 10.1080/10428194.2016.1196816. Epub 2016 Jun 27.
3
V617F mutation to calreticulin mutation in an essential thrombocythemia patient: A case report.原发性血小板增多症患者中V617F突变向钙网蛋白突变的转变：一例报告。
Indian J Cancer. 2021 Jul-Sep;58(3):431-433. doi: 10.4103/ijc.IJC_106_20.
4
A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia.一名原发性血小板增多症患者中涉及第14内含子剪接区域的新型Janus激酶2突变。
Leuk Lymphoma. 2009 Dec;50(12):2089-91. doi: 10.3109/10428190903308023.
5
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.钙网蛋白突变不会改变1150例原发性血小板增多症患者中用于预测血栓形成风险的IPSET评分。
Blood. 2014 Oct 16;124(16):2611-2. doi: 10.1182/blood-2014-08-596676.
6
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia.真性红细胞增多症中根据JAK2V617F突变状态分析CD34+干/祖细胞的分子特征
Leukemia. 2009 May;23(5):997-1000. doi: 10.1038/leu.2008.357. Epub 2009 Jan 8.
7
The mutant JAK2 allele burden in children with essential thrombocythemia.原发性血小板增多症患儿中突变型JAK2等位基因负荷
Br J Haematol. 2009 May;145(3):430-2. doi: 10.1111/j.1365-2141.2009.07591.x. Epub 2009 Feb 4.
8
Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.在伴有JAK2（V617F）突变的原发性血小板增多症的任何阶段都可能发生血栓形成：日本一项单中心研究
Leukemia. 2007 Jul;21(7):1570-1. doi: 10.1038/sj.leu.2404666. Epub 2007 Mar 29.
9
JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia.JAK2 V617F、止血多态性及临床特征作为原发性血小板增多症患者动脉血栓形成事件的危险因素
Ann Hematol. 2008 Sep;87(9):763-5. doi: 10.1007/s00277-008-0474-z. Epub 2008 Mar 26.
10
Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis.通过高分辨率熔解分析在JAK2 V617F突变的原发性血小板增多症中检测到频繁的CALR外显子9改变。
Blood Cancer J. 2015 Mar 20;5(3):e295. doi: 10.1038/bcj.2015.21.

本文引用的文献

1
Triple a score (AAA: age, absolute neutrophil count and absolute lymphocyte count) and its prognostic utility in patients with overt fibrotic and prefibrotic myelofibrosis.三联a评分（AAA：年龄、绝对中性粒细胞计数和绝对淋巴细胞计数）及其在明显纤维化和纤维化前骨髓纤维化患者中的预后效用。
Ann Hematol. 2024 Jun;103(6):2157-2159. doi: 10.1007/s00277-024-05751-7. Epub 2024 Apr 23.
2
The triple A model (age, absolute neutrophil count, absolute lymphocyte count-AAA) predicts survival and thrombosis in polycythemia vera.三联A模型（年龄、中性粒细胞绝对计数、淋巴细胞绝对计数-AAA）可预测真性红细胞增多症的生存率和血栓形成情况。
Am J Hematol. 2024 May;99(5):989-992. doi: 10.1002/ajh.27261. Epub 2024 Feb 23.
3
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.
接受芦可替尼治疗的骨髓纤维化患者中性粒细胞与淋巴细胞比值可预测预后和停药率。
Eur J Haematol. 2024 Jun;112(6):938-943. doi: 10.1111/ejh.14188. Epub 2024 Feb 9.
4
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.原发性血小板增多症：2024 年诊断、风险分层和治疗更新。
Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25.
5
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.基于年龄、绝对中性粒细胞计数和绝对淋巴细胞计数的全球适用的原发性血小板增多症“三重 A”风险模型。
Am J Hematol. 2023 Dec;98(12):1829-1837. doi: 10.1002/ajh.27079. Epub 2023 Sep 4.
6
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.中性粒细胞与淋巴细胞比值是真性红细胞增多症静脉血栓形成的新预测因子。
Blood Cancer J. 2022 Feb 10;12(2):28. doi: 10.1038/s41408-022-00625-5.
7
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in polycythemia vera.中性粒细胞与淋巴细胞比值及血小板与淋巴细胞比值作为真性红细胞增多症的预后生物标志物
Int J Lab Hematol. 2022 Aug;44(4):e145-e148. doi: 10.1111/ijlh.13786. Epub 2021 Dec 30.
8
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia.解读真性红细胞增多症和原发性血小板增多症中绝对中性粒细胞计数和单核细胞计数对血栓形成风险的个体贡献。
Am J Hematol. 2022 Feb 1;97(2):E35-E37. doi: 10.1002/ajh.26423. Epub 2021 Dec 6.
9
Definition of major bleeding: Prognostic classification.大出血的定义：预后分类。
J Thromb Haemost. 2020 Nov;18(11):2852-2860. doi: 10.1111/jth.15048. Epub 2020 Sep 11.
10
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.突变增强的原发性血小板增多症和真性红细胞增多症国际预后系统。
Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16.